5-AMINO-1MQ 50MG – 60CT

5-AMINO-1MQ CAPSULES 50MG – 60CT

5-Amino-1MQ (5-amino-1-methylquinolinium) is a selective small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme overexpressed in obesity, aging, and certain cancers, and metabolic disorders. By inhibiting NNMT, 5-Amino-1MQ prevents the methylation of nicotinamide, thereby increasing intracellular NAD⁺ levels. This shift activates sirtuins (especially SIRT1), enhances mitochondrial function, promotes fat oxidation, and improves insulin sensitivity. Preclinical studies in diet-induced obese mice show up to 7% body weight reduction and ~30% fat mass loss without altering food intake.^[1][2]

Key Research Areas

• Metabolic Regulation & Obesity – Reduces adipocyte size ~30%, fat mass ~30–40%, and de novo lipogenesis 50–70% in DIO mice via NAD⁺/SIRT1 upregulation.^[1][3]
• Muscle Regeneration & Sarcopenia – Enhances muscle stem cell proliferation and restores regenerative capacity in aged mice after injury; improves peak torque recovery by ~70%.^[4]
• Longevity Pathways – Elevates NAD⁺, activates sirtuins, improves mitochondrial biogenesis, insulin sensitivity, and resistance to age-related metabolic decline.^[2][5]

Product Specifications

References

1. 1. Neelakantan H, et al. Selective targeting of NNMT in obesity and type 2 diabetes. Cell Metab. 2019. PubMed
2. 2. Neelakantan H, et al. NNMT inhibition dramatically improves healthspan and metabolic health. Nat Commun. 2021. PubMed
3. 3. Bramblett JW, et al. Small-molecule NNMT inhibitor reduces body weight and fat mass. J Pharmacol Exp Ther. 2022. PubMed
4. 4. Wang Y, et al. NNMT inhibition rescues muscle stem cell senescence. Aging Cell. 2023. PubMed
5. 5. Rajman L, et al. Therapeutic potential of NAD-boosting molecules. Cell Metab. 2018. PubMed